The Dual Blockade of the TIGIT and PD-1/PD-L1 Pathway as a New Hope for Ovarian Cancer Patients.
TIGIT
clinical trials
dual blockade
immunotherapy
ovarian cancer
programmed cell death pathway
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
23 Nov 2022
23 Nov 2022
Historique:
received:
21
10
2022
revised:
17
11
2022
accepted:
19
11
2022
entrez:
11
12
2022
pubmed:
12
12
2022
medline:
12
12
2022
Statut:
epublish
Résumé
The prognosis for ovarian cancer (OC) patients is poor and the five-year survival rate is only 47%. Immune checkpoints (ICPs) appear to be the potential targets in up-and-coming OC treatment. However, the response of OC patients to immunotherapy based on programmed cell death pathway (PD-1/PD-L1) inhibitors totals only 6-15%. The promising approach is a combined therapy, including other ICPs such as the T-cell immunoglobulin and ITIM domain/CD155/DNAX accessory molecule-1 (TIGIT/CD155/DNAM-1) axis. Preclinical studies in a murine model of colorectal cancer showed that the dual blockade of PD-1/PD-L1 and TIGIT led to remission in the whole studied group vs. the regression of the tumors with the blockade of a single pathway. The approach stimulates the effector activity of T cells and NK cells, and redirects the immune system activity against the tumor. The understanding of the synergistic action of the TIGIT and PD-1/PD-L1 blockade is, however, poor. Thus, the aim of this review is to summarize the current knowledge about the mode of action of the dual TIGIT and PD-1/PD-L1 blockade and its potential benefits for OC patients. Considering the positive impact of this combined therapy in malignancies, including lung and colorectal cancer, it appears to be a promising approach in OC treatment.
Identifiants
pubmed: 36497240
pii: cancers14235757
doi: 10.3390/cancers14235757
pmc: PMC9740841
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : National Science Center
ID : 2021/41/N/NZ6/01727
Références
Curr Oncol Rep. 2019 Jul 26;21(8):75
pubmed: 31346778
Curr Treat Options Oncol. 2022 Apr;23(4):578-593
pubmed: 35312963
Int J Gynecol Cancer. 2017 Jan;27(1):11-16
pubmed: 27759594
Ther Adv Med Oncol. 2021 Aug 18;13:17588359211039899
pubmed: 34422119
J Biol Chem. 2020 Apr 3;295(14):4372-4380
pubmed: 31882544
J Immunother Cancer. 2020 Nov;8(2):
pubmed: 33188038
Oncoimmunology. 2019 Oct 12;8(12):e1674605
pubmed: 31741778
J Immunol. 2004 Apr 1;172(7):3994-8
pubmed: 15034010
Immunity. 2022 Mar 8;55(3):512-526.e9
pubmed: 35263569
Ann Oncol. 2019 Jul 1;30(7):1080-1087
pubmed: 31046082
Cancers (Basel). 2019 Jun 23;11(6):
pubmed: 31234588
Biosci Rep. 2021 Mar 26;41(3):
pubmed: 33721026
Front Pharmacol. 2021 Jul 05;12:678409
pubmed: 34290608
Oncoimmunology. 2020 Nov 8;9(1):1843247
pubmed: 33224630
Mol Ther Oncolytics. 2020 Feb 15;16:289-301
pubmed: 32195317
Oncol Lett. 2020 Nov;20(5):204
pubmed: 32963610
J Dtsch Dermatol Ges. 2020 Jun;18(6):582-609
pubmed: 32489011
J Oncol. 2022 Sep 15;2022:8570882
pubmed: 36157232
J Immunother Cancer. 2019 Jun 25;7(1):160
pubmed: 31238970
Int Immunopharmacol. 2017 Jun;47:244-250
pubmed: 28437737
Cancer Immunol Immunother. 2017 Oct;66(10):1367-1375
pubmed: 28623459
Cancer Immunol Immunother. 2021 Oct;70(10):2781-2793
pubmed: 33634371
Transl Cancer Res. 2019 Feb;8(1):111-119
pubmed: 35116740
Cancer Sci. 2010 May;101(5):1326-30
pubmed: 20331633
Cell Res. 2020 Apr;30(4):285-299
pubmed: 31974523
Annu Rev Immunol. 2008;26:677-704
pubmed: 18173375
Gynecol Oncol Rep. 2019 Jun 18;29:48-54
pubmed: 31312712
F1000Res. 2020 May 13;9:
pubmed: 32489646
Cancer Manag Res. 2020 Oct 07;12:9691-9709
pubmed: 33116828
Oncol Lett. 2018 May;15(5):7312-7318
pubmed: 29725446
Front Oncol. 2021 Dec 13;11:795547
pubmed: 34966689
Gynecol Oncol. 2019 Feb;152(2):251-258
pubmed: 30470581
J Immunol. 2015 Jul 1;195(1):145-55
pubmed: 25994968
Onco Targets Ther. 2020 Jun 26;13:6109-6129
pubmed: 32617007
Clin Cancer Res. 2022 Aug 15;28(16):3590-3602
pubmed: 35675036
Cancers (Basel). 2018 Jul 24;10(8):
pubmed: 30042343
Immunol Rev. 2008 Aug;224:166-82
pubmed: 18759926
Clin Cancer Res. 2017 Jul 1;23(13):3453-3460
pubmed: 27986748
Clin Cancer Res. 2021 Aug 1;27(15):4435-4448
pubmed: 34011561
Gynecol Oncol. 2012 Feb;124(2):192-8
pubmed: 22040834
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32503945
Biomedicines. 2021 Sep 21;9(9):
pubmed: 34572463
Cancer Treat Rev. 2017 Jun;57:36-49
pubmed: 28550712
Biomed Pharmacother. 2019 Jul;115:108884
pubmed: 31035013
J Clin Invest. 2015 May;125(5):2046-58
pubmed: 25866972
Trends Immunol. 2017 Jan;38(1):20-28
pubmed: 27793572
Eur J Immunol. 2013 Aug;43(8):2138-50
pubmed: 23677581
Biochem Biophys Res Commun. 2020 Oct 15;531(2):144-151
pubmed: 32782142
Cancer Biol Med. 2019 Nov;16(4):655-670
pubmed: 31908886
Nat Immunol. 2009 Jan;10(1):48-57
pubmed: 19011627
Semin Oncol Nurs. 2019 Apr;35(2):151-156
pubmed: 30867104
Nat Rev Drug Discov. 2021 Aug;20(8):576
pubmed: 34239092
Surg Today. 2015 Apr;45(4):487-94
pubmed: 25690753
Elife. 2019 Nov 26;8:
pubmed: 31767055
Clin Cancer Res. 2016 Nov 1;22(21):5183-5188
pubmed: 27620276
Front Immunol. 2022 Jun 03;13:911919
pubmed: 35720417
J Gynecol Oncol. 2017 Sep;28(5):e64
pubmed: 28657225
Structure. 2016 Oct 4;24(10):1719-1728
pubmed: 27618663
Clin Cancer Res. 2021 Apr 1;27(7):1932-1940
pubmed: 33408249
Proc Natl Acad Sci U S A. 2022 Apr 26;119(17):e2117065119
pubmed: 35467979
Cancer Sci. 2017 Oct;108(10):1934-1938
pubmed: 28730595
Front Immunol. 2022 Jun 24;13:914406
pubmed: 35812451
Semin Cancer Biol. 2020 Oct;65:189-196
pubmed: 31883911
Acta Obstet Gynecol Scand. 2022 Sep;101(9):941-951
pubmed: 35751489
Oncoimmunology. 2018 May 24;7(8):e1466769
pubmed: 30221069
Cancers (Basel). 2020 Dec 18;12(12):
pubmed: 33352957
Science. 2017 Mar 31;355(6332):1428-1433
pubmed: 28280247
Cancer Immunol Immunother. 2018 Nov;67(11):1659-1667
pubmed: 30232519
Front Immunol. 2021 Sep 29;12:688961
pubmed: 34659197
Clin Exp Immunol. 2019 Mar;195(3):334-344
pubmed: 30582756
Lancet Oncol. 2022 Jun;23(6):781-792
pubmed: 35576957
Cancer Immunol Res. 2019 Feb;7(2):257-268
pubmed: 30659054
Proc Natl Acad Sci U S A. 2009 Oct 20;106(42):17858-63
pubmed: 19815499
Cells. 2022 Mar 11;11(6):
pubmed: 35326415
Expert Opin Emerg Drugs. 2021 Jun;26(2):79-92
pubmed: 33686894
Mol Cancer. 2020 May 2;19(1):81
pubmed: 32359357
Clin Cancer Res. 2020 Oct 15;26(20):5274-5275
pubmed: 32817077
Cochrane Database Syst Rev. 2014 Feb 21;(2):CD009786
pubmed: 24563459
Am J Cancer Res. 2019 Aug 01;9(8):1546-1553
pubmed: 31497342
Anticancer Res. 2015 Apr;35(4):2287-97
pubmed: 25862891
Clin Cancer Res. 2021 Jul 15;27(14):4089-4100
pubmed: 33963000
Int J Mol Sci. 2021 Oct 26;22(21):
pubmed: 34768993
Cancers (Basel). 2021 Sep 03;13(17):
pubmed: 34503248
Fertil Steril. 2022 Jan;117(1):169-170
pubmed: 34865852
World J Clin Oncol. 2019 Jul 24;10(7):247-255
pubmed: 31396474
Br J Cancer. 2019 Jan;120(1):115-127
pubmed: 30382166
Cancer Immunol Res. 2019 Oct;7(10):1700-1713
pubmed: 31387897
Front Immunol. 2022 Jun 27;13:901772
pubmed: 35833132
Int Immunol. 2021 Nov 25;33(12):687-692
pubmed: 34694361
Nat Immunol. 2018 Jul;19(7):723-732
pubmed: 29915296
Cancers (Basel). 2021 Dec 01;13(23):
pubmed: 34885169
Hepatology. 2021 Apr;73(4):1399-1418
pubmed: 32716559
Med Sci Monit. 2018 Sep 28;24:6861-6872
pubmed: 30262800
Oncotarget. 2018 Oct 5;9(78):34810-34820
pubmed: 30410679
Monoclon Antib Immunodiagn Immunother. 2021 Apr;40(2):71-75
pubmed: 33900817
Cancer Med. 2020 May;9(10):3584-3591
pubmed: 32212317
Curr Top Dev Biol. 2015;112:197-231
pubmed: 25733141
Immunol Invest. 2017 Feb;46(2):172-182
pubmed: 27819527
J Immunother Cancer. 2022 Apr;10(4):
pubmed: 35379739
J Clin Med. 2021 Dec 17;10(24):
pubmed: 34945222
J Clin Invest. 2015 Nov 2;125(11):4053-62
pubmed: 26413872
CA Cancer J Clin. 2019 Jul;69(4):280-304
pubmed: 31099893
J Invest Dermatol. 2016 Jan;136(1):255-63
pubmed: 26763445
Cancer Med. 2020 Apr;9(8):2643-2652
pubmed: 32074405
J Immunol. 2018 Apr 15;200(8):3000-3007
pubmed: 29500245
Immunity. 2020 Oct 13;53(4):824-839.e10
pubmed: 33053331
PLoS One. 2016 Apr 06;11(4):e0152982
pubmed: 27049654
Front Immunol. 2020 Oct 06;11:577869
pubmed: 33123161
Front Oncol. 2020 Sep 17;10:554313
pubmed: 33072580
Biochem J. 2016 Sep 15;473(18):2691-715
pubmed: 27621480
J Exp Clin Cancer Res. 2021 Aug 25;40(1):267
pubmed: 34433460
Oncol Lett. 2019 Mar;17(3):2960-2968
pubmed: 30854074
J Exp Med. 2016 Feb 8;213(2):167-76
pubmed: 26755705
Front Immunol. 2021 Jul 22;12:699895
pubmed: 34367161
Sci Immunol. 2018 Nov 2;3(29):
pubmed: 30389797
Oncotarget. 2012 Aug;3(8):882-92
pubmed: 22929570
J Clin Invest. 2018 Jun 1;128(6):2613-2625
pubmed: 29757192
J Biol Chem. 2017 Jul 7;292(27):11413-11422
pubmed: 28515320
Exp Cell Res. 2020 Nov 1;396(1):112260
pubmed: 32890458
Oncoimmunology. 2017 Nov 9;7(2):e1387705
pubmed: 29308313
Pharmaceuticals (Basel). 2021 Feb 28;14(3):
pubmed: 33670993
Biomed Pharmacother. 2019 Feb;110:139-144
pubmed: 30469078
Arch Immunol Ther Exp (Warsz). 2022 Aug 9;70(1):19
pubmed: 35941287
Gut. 2001 Aug;49(2):236-40
pubmed: 11454801
J Exp Med. 2020 Mar 2;217(4):
pubmed: 32040157
Cancer Chemother Pharmacol. 2018 Jan;81(1):17-38
pubmed: 29249039
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:59-78
pubmed: 30306591
Cancer Cell. 2014 Dec 8;26(6):923-937
pubmed: 25465800
Mol Cancer Ther. 2021 Jan;20(1):121-131
pubmed: 33277440
J Ovarian Res. 2019 Nov 4;12(1):103
pubmed: 31685032
Drugs. 2016 Jun;76(9):925-45
pubmed: 27229745
Cancers (Basel). 2020 Nov 09;12(11):
pubmed: 33182298
Cancer Immunol Immunother. 2020 Jan;69(1):33-42
pubmed: 31781843
Gynecol Oncol. 2020 Jul;158(1):167-177
pubmed: 32446718
Immunol Rev. 2017 Mar;276(1):112-120
pubmed: 28258695
Front Oncol. 2019 Oct 15;9:1073
pubmed: 31681606
Cancer Immunol Immunother. 2021 Dec;70(12):3525-3540
pubmed: 33903974
Clin Exp Immunol. 2020 May;200(2):108-119
pubmed: 31828774
J Clin Invest. 2013 Jan;123(1):517-25
pubmed: 23257362
J Immunother Cancer. 2020 Sep;8(2):
pubmed: 32900861
Proc Natl Acad Sci U S A. 2015 May 26;112(21):6682-7
pubmed: 25964334
J Immunol. 2009 Oct 15;183(8):4921-30
pubmed: 19801517